Effects of hydrochlorthiazide and spironolactone in tratement of kidney involvement in diabetic patient

Effects of hydrochlorthiazide and spironolactone in reducing of proteinuria in patients with diabetic nephropathy treated by angiotensin coverting enzyme inhibitors

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201408083742N2

Enrollment

Registered

2014-10-15

Start date

2014-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: First group: Spironolactone 25 mg daily for 3 month. Intervention 2: Second group: Hydrochlorthiazide 25 mg daily for 3 month.

Treatment - Drugs

First group: Spironolactone 25 mg daily for 3 month

Second group: Hydrochlorthiazide 25 mg daily for 3 month

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: blood pressure>130/80 under treatment with ACEIs; proteinuria>150 mg/24hr Exclusion criteria: serum potasium>5 meq/L; GFR<30 ml/min; proteinuria due to other conditions such as UTI or CHF

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Proteinuria. Timepoint: before and 3 month after study. Method of measurement: 24 hr urine collection.	—

Secondary

Measure	Time frame
Blood pressure. Timepoint: before and 1 week and 1 and 3 month after study. Method of measurement: barometer(mmhg).;Serum potasium. Timepoint: before and 1 week and 1 and 3 month after study. Method of measurement: biochemical test(meq/L).;Serum sodium. Timepoint: before and 3 month after study. Method of measurement: biochemical test(meq/L).;Serum cratinin. Timepoint: before and 3 month after study. Method of measurement: biochemical test(mgr/dl).;Serum urea. Timepoint: before and 3 month after study. Method of measurement: biochemical test(mgr/dl).;Serum albumin. Timepoint: before and 3 month after study. Method of measurement: biochemical test(gr/dl).;24hr urine volume. Timepoint: before and 3 month after study. Method of measurement: biochemical test(mililiter).;24hr urine creatinin. Timepoint: before and 3 month after study. Method of measurement: biochemical test(miligram).;Albumin/creatinin ratio. Timepoint: before and 3 month after study. Method of measurement: biochemical test.;Glumerolar filtration. Timepoint: before and 3 month after study. Method of measurement: Cockcroft-Gault equation.	—

Measure

Time frame

Blood pressure. Timepoint: before and 1 week and 1 and 3 month after study. Method of measurement: barometer(mmhg).;Serum potasium. Timepoint: before and 1 week and 1 and 3 month after study. Method of measurement: biochemical test(meq/L).;Serum sodium. Timepoint: before and 3 month after study. Method of measurement: biochemical test(meq/L).;Serum cratinin. Timepoint: before and 3 month after study. Method of measurement: biochemical test(mgr/dl).;Serum urea. Timepoint: before and 3 month after study. Method of measurement: biochemical test(mgr/dl).;Serum albumin. Timepoint: before and 3 month after study. Method of measurement: biochemical test(gr/dl).;24hr urine volume. Timepoint: before and 3 month after study. Method of measurement: biochemical test(mililiter).;24hr urine creatinin. Timepoint: before and 3 month after study. Method of measurement: biochemical test(miligram).;Albumin/creatinin ratio. Timepoint: before and 3 month after study. Method of measurement: biochemical test.;Glumerolar filtration. Timepoint: before and 3 month after study. Method of measurement: Cockcroft-Gault equation.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Taher Manzary

Tabriz University of Medical Sciences

manzarytaher@yahoo.com+98 41 3442 9017

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026